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Crossing the Spasm Sudden Death Chasm*
L. Brent Mitchell, MD
Calgary, Alberta, Canada
“The variant form of angina pectoris may follow a variety of
courses during its natural development. Death may occur during
an attack, probably from ventricular fibrillation.”
—Myron Prinzmetal et al. (1), 1959
Large, randomized clinical trials have demonstrated that the
implantable cardioverter defibrillator (ICD) reduces sudden
cardiac death mortality, and thereby all-cause mortality, in
patients who have been resuscitated from an episode of
spontaneous life-threatening ventricular tachycardia (VT)
or ventricular fibrillation (VF [secondary prevention of
sudden cardiac death]) (2), and in certain patients deemed
See page 908
to be at high risk of having an episode of life-threatening
VT/VF (primary prevention of sudden cardiac death) (3).
The relative risk reduction in arrhythmic death in these
trials approached 60% and was entirely responsible for a
relative risk reduction in all-cause mortality of 30% (4).
The patient populations in these trials were dominated by
those with compromised left ventricular systolic function
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idiopathic congestive cardiomyopathy. Accordingly, unequivocal
evidence for the ICD representing lifesaving therapy in patients
with any of the many other predisposing causes of VT/VF does
not exist. Nevertheless, it is common practice to prescribe an
ICD for patients whose annual risk of sudden cardiac death
is equal to or greater than the approximate 3% to 4% annual
risk of sudden cardiac death observed in the control patient
populations of these trials (2–5). Relative to the secondary
prevention of sudden cardiac death, current guidelines (6)
provide a Class I recommendation to insert an ICD in
“patients who are survivors of cardiac arrest due to VF or
hemodynamically unstable sustained VT after evaluation to
define the cause of the event and to exclude any completely
reversible causes.” Relative to the primary prevention of
sudden cardiac death, current guidelines (6) provide a Class
I recommendation to insert an ICD only in patients well
represented in the randomized ICD clinical trials discussed.
Nevertheless, Class IIa recommendations to insert an
ICD are provided for a number of less common arrhyth-
mogenic conditions that have not been studied in random-
ized controlled clinical trials. These guideline recommen-
dations are predicated on either the assumption of or
observational trial evidence that: 1) a patient population
with an uncommon arrhythmogenic condition can be iden-
tified with a predicted sudden cardiac death probability
similar to the 3% to 4% per year event rate seen in the
control groups of the randomized ICD trials; 2) this sudden
cardiac death risk is not transient or reversible; 3) ICD
therapy is capable of terminating VT/VF and thereby
preventing sudden death in this setting; and 4) there are not
frequent competing causes of mortality that would negate
any survival advantage for the prevention of sudden cardiac
death. The current guidelines (6) are silent with respect to
use of an ICD in patients with coronary artery vasospasm,
presumably because these conditions have not yet been met.
Observational trials of patients with coronary artery
vasospasm who are receiving medical treatment with cal-
cium antagonists report an annual cardiac arrest or sudden
cardiac death risk of approximately 0.6% per year (7).
Independent risk factors for adverse cardiac events in
patients with coronary artery vasospasm include a history of
out-of-hospital cardiac arrest (hazard ratio [HR]: 3.25; 95%
confidence interval [CI]: 1.39 to 7.61; p  0.007), signifi-
cant structural coronary artery stenosis (HR: 2.04; 95% CI:
1.21 to 3.44; p  0.008), ST-segment elevation during
spontaneous vasospasm (HR: 1.77; 95% CI: 1.09 to 2.87;
p  0.022), multivessel spasm (HR: 1.62; 95% CI: 1.03 to
2.56; p  0.037), and continued smoking (HR: 1.67; 95%
CI: 1.02 to 2.73; p  0.041) (8). Standard medical therapy
for patients with coronary artery vasospasm consists of calcium
antagonist therapy with or without concomitant nitrate ther-
apy, smoking cessation, avoidance of beta-blocker drug ther-
apy, and use of an 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG CoA) reductase inhibitor (statin) (9).
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ing the annual risk of sudden cardiac death among patients
with coronary artery vasospasm who have presented with an
out-of-hospital cardiac arrest and then receive optimal
medical therapy with respect to their subsequent annual risk
of sudden death and with respect to the efficacy of ICD
therapy in this setting.
In this issue of the Journal, Matsue et al. (10) provide the
results of a retrospective observational trial focused on 23
apparently consecutive patients from 3 Japanese hospitals
who had received a secondary prevention ICD after resus-
citation from an episode of life-threatening VT/VF in the
absence of structural heart disease or coronary artery disease
who had spasm of a major epicardial coronary artery induced
with acetylcholine challenge. Over a mean follow-up period of
2.9 years, 4 patients had an episode of VF appropriately
treated by their ICD and survived, and 1 additional patient
had a cardiac arrest secondary to pulseless electrical activity
and survived. These data provide an estimate of the annual
probability of sudden cardiac death secondary to VT/VF in
such patients: approximately 6% per year. This estimate
exceeds the 3% to 4% annual risk of the control patient
populations of the randomized ICD trials. Although it is
clear that incidence of the surrogate endpoint of appropriate
ICD therapy for VT/VF exceeds that of the incidence of
sudden cardiac death, the overestimate provided by use of
this surrogate endpoint in this instance, where all treated
events were VF, is not expected to be as large as the 2:1 ratio
observed in the SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial) study (5,11). These events occurred
despite optimal medical therapy of coronary artery vaso-
spasm (although 1 patient with ICD-treated VF had dis-
continued his medical treatment) and occurred in the
absence of premonitory changes in the patients’ symptom-
atic states. This evidence, that the risk of sudden cardiac
death in this setting is not transient, reversible, or predict-
able despite medical therapy, is supported by other obser-
vational trials (7,12,13). The results of the report of Matsue
et al. (10) also indicate that ICD therapy is effective for the
termination of VF and for the secondary prevention of
sudden cardiac death in patients with coronary artery
vasospasm, and that competing causes of mortality in these
patients in the absence of significant structural coronary
artery disease are infrequent.
These observations support the use of ICD therapy in
patients with coronary artery vasospasm who have survived
an episode of life-threatening VT/VF. Nevertheless, many
questions remain. First, it is not yet clear that the risk of
recurrent VT/VF is enduring in this patient population.
Although is not wise to overinterpret the shape of a
Kaplan-Meier curve, from the data presented by Matsue
et al. (10), all of the recurrent events occurred within the
first 2 years of follow-up, and none of the patients with a
recurrent event had a second recurrent event. Whether
the apparent benefit of an ICD in this patient populationis time limited can only be determined by very long-term
follow-up.
Second, it is noteworthy that the patients described in the
report of Matsue et al. (10) also had, in addition to the risk
predictor of spontaneous life-threatening VT/VF, other risk
factors for future adverse cardiac events including a high
proportion (more than half) who had multivessel coronary
spasm.
Third, this trial and most of the contemporary reports of
large patient populations with coronary artery vasospasm
have exclusively considered Japanese patients, raising the
question as to the external validity of their results in other
ethnic groups. Although it is clear that the incidence of
coronary artery vasospasm is higher in the Japanese popu-
lation than in the populations of North America or Western
Europe (9), there is no compelling evidence that the natural
history of a patient with documented coronary artery spasm
and spontaneous life-threatening VT/VF differs by ethnicity
or location.
Fourth, larger population of patients with coronary artery
vasospasm treated with an ICD will be required to deter-
mine if there are unique potential complications of an ICD
in this setting in addition to the previously reported possi-
bility of ICD oversensing of the ventricular repolarization
changes that accompany a spontaneous episode of coronary
artery vasospasm (14).
Finally, this report also suggests that there may be value
in provocative testing for coronary artery spasm in patients
who have experienced life-threatening VT/VF in the ab-
sence of an identifiable cause so that patients with demon-
strated coronary artery spasm could also benefit from the
advantages of vasodilator therapy. Although this association
is not considered to be frequent in North America, a
previous report from the West estimated that approximately
one-third of patients with life-threatening VT/VF in the
absence of structural heart disease have coronary artery
spasm and silent myocardial ischemia responsible for their
arrhythmia (15).
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